MDxHealth (NASDAQ:MDXH – Get Free Report) and Schrodinger (NASDAQ:SDGR – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, risk, earnings, valuation and institutional ownership.
Analyst Ratings
This is a summary of recent ratings for MDxHealth and Schrodinger, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| MDxHealth | 1 | 0 | 4 | 0 | 2.60 |
| Schrodinger | 1 | 4 | 5 | 0 | 2.40 |
MDxHealth currently has a consensus price target of $7.75, suggesting a potential upside of 104.49%. Schrodinger has a consensus price target of $24.33, suggesting a potential upside of 48.19%. Given MDxHealth’s stronger consensus rating and higher possible upside, equities analysts clearly believe MDxHealth is more favorable than Schrodinger.
Earnings & Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| MDxHealth | $90.05 million | 1.99 | -$38.07 million | ($0.64) | -5.92 |
| Schrodinger | $207.54 million | 5.83 | -$187.12 million | ($2.41) | -6.81 |
MDxHealth has higher earnings, but lower revenue than Schrodinger. Schrodinger is trading at a lower price-to-earnings ratio than MDxHealth, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares MDxHealth and Schrodinger’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| MDxHealth | -30.50% | -1,078.01% | -20.05% |
| Schrodinger | -68.49% | -48.24% | -24.21% |
Insider and Institutional Ownership
79.1% of Schrodinger shares are owned by institutional investors. 1.7% of MDxHealth shares are owned by company insiders. Comparatively, 21.0% of Schrodinger shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Volatility and Risk
MDxHealth has a beta of 1.62, meaning that its stock price is 62% more volatile than the S&P 500. Comparatively, Schrodinger has a beta of 1.54, meaning that its stock price is 54% more volatile than the S&P 500.
Summary
MDxHealth beats Schrodinger on 8 of the 14 factors compared between the two stocks.
About MDxHealth
MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection. The company offers genomic prostate score which provides personalized genomic insights to both physicians and patients navigating the complexities of prostate cancer diagnosis and treatment. It sells its products through urology sales force, consisting of direct sales representatives, strategic account managers, and regional sales managers. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.
About Schrodinger
Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.
Receive News & Ratings for MDxHealth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MDxHealth and related companies with MarketBeat.com's FREE daily email newsletter.
